The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
There's no issue with the current revenue stream. The main question is how quickly the new CEO can get on top of the cost base and bring the net monthly operating cashflow back above zero. Once he can achieve this, and report it, the SP will move sharply northwards IMO.
I'm now looking forward to the company confirming that the in-house Analytical Release tests have gone according to plan and also the outcome of the third part quality tests needed for the IND. Investor anticipation will no doubt start to grow as the week goes on. Happy to hold here.
Possibly, although it is rumoured that Lord Lucan is on the case.
I agree, as it provides Hemo with the opportunity to remove any remaining ambiguity from the Car T product application planning process. Almost at break even but am holding for the forseeable. GLA
Also it's good to see a healthy (2:1) buy to sell ratio - for a change :)
Full asking @1.80 just paid. Perking up a bit at last - not getting my hopes up too much, but who knows maybe a material update is imminent?
It's on m8y the penny is dropping fast now :)
Bitcoin recovering now above 56200. Already about 20pc off its 68000 high a few weeks ago so already a big correction.
3.6 to buy - some upward momentum gathering. :-)
About time Hemo's potential was recognised. News must be close, so I have lifted my stop loss as it has started a second surge :-) GLA.
I agree this article only gives a backward looking snapshot of the Financial statements and doesn't bother to try and assess the earnings potential of the product pipeline. Maybe next time!
A placing like this is never welcome but I wonder how much of the (future) Mint conversions were already priced in to the SP? I guess we are about to find out...
From a commodity markets perspective Tin is more than holdng its own. up another 2.4% up today. The conditions are incredibly ripe for Redmoor. What more incentive do the BoD need to deliver on their promises?
Given the mkt cap of £22m. Headlines disappointing but most of this impact was anticipated and priced in. Good progress on leases and improved online performance means FCCN should continue to recover IMO.
Today's price move shows it is well worth being patient. We can't be too far off a key business update now. Loads of possibilities for FAB to increase shareholder value in this rapidly developing market . GLA
Would tend to agree with you JWO, just looking at their R & D project pipeline and its potential revenue impact - without factoring in the monetisation of its key Covid 19 target which is a separate discussion entirely. The current market cap at £27m hardly scratches the surface of the value to be realised in the next few months as further news is released. IMO so has to be a good buy at these levels. GLA.
Waited ages to top up my holding but finally did so at £1.39 just before today's bell. So the last trade today should definitely show up in blue :) GLA.
Count me in too. 2m held here.
Potentially a Trading Update, which I think is due shortly if previous intervals are anything to go by.
Shaping up well for for possible game changing news e.g. on partnering developments next week? Not many shares in circulation here so will be sought after - requires sticky hands.